What is TSC?
What is facial angiofibroma?
Facial angiofibroma is one of the most predominant skin lesions in TSC. They are pink-to-red papules or nodules that are typically located on the cheeks, nose, and chin.2
What FDA-approved topical treatments were previously available to treat facial angiofibroma?
What is HYFTOR?
How can HYFTOR help treat facial angiofibroma?
How can I prescribe HYFTOR?
Nobelpharma is committed to making access as simple and seamless as possible with specialty pharmacy services, including expediting the initiation of patient therapy.
We also offer Nobelpharma Connect to help patients fill prescriptions for HYFTOR as simply and seamlessly as possible.
When will HYFTOR be available in the United States?
HYFTOR is already approved by the FDA. HYFTOR will be available in October 2021. However, you can enroll patients now to help ensure a seamless transition.
The use of HYFTOR™ (sirolimus topical gel) 0.2% may cause local symptoms such as irritation (dry skin, dermatitis,
erythema, pruritus, acne). Localized symptoms are most common. Patients should be cautioned to stay out of direct
Please see accompanying Full Prescribing Information.